Form 4: Precision BioSciences CFO John Alexander Kelly Reports Acquisition of Restricted Stock Units

John Alexander Kelly, CFO of Precision BioSciences, reports the acquisition of 79,725 restricted stock units.

Summary

• On August 22, 2024, John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, acquired 79,725 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Precision BioSciences' Common Stock.
• The RSUs vest in three substantially equal annual installments beginning on January 20, 2025, contingent upon Kelly's continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard executive compensation practice. The acquisition of RSUs is generally viewed as a positive sign, indicating alignment between management and shareholder interests, but it's not a major event.

Positives

• The vesting schedule incentivizes the CFO to remain with the company for at least three years.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating alignment of interests between management and shareholders.
• Employees may see this as a sign of stability and commitment from the CFO.

Key Dates